Researchers at the National Biologics Facility (NBF) at The University of Queensland will benefit from a substantial funding boost for COVID-19 research.
The NBF specialises in the production of high-quality proteins with potential therapeutic or commercial uses, and its state-of-the-art laboratories housed in UQ’s AIBN are playing a central role in the development of vaccines and other therapeutics to fight COVID-19.
The NBF, which has previously benefitted from Queensland and Federal governments funding, welcomed the news that the National Collaborative Research Infrastructure Scheme (NCRIS) had awarded $1.2 million to the not-for-profit research infrastructure organisation Therapeutic Innovation Australia (TIA).
Comments